-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ChromaDex (NASDAQ:CDXC) PT Lowered to $5.50
ChromaDex (NASDAQ:CDXC) PT Lowered to $5.50
ChromaDex (NASDAQ:CDXC – Get Rating) had its price target reduced by HC Wainwright from $7.00 to $5.50 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other equities research analysts have also issued reports on CDXC. B. Riley lowered shares of ChromaDex from a buy rating to a neutral rating and decreased their target price for the company from $6.00 to $2.40 in a research note on Thursday, August 11th. Oppenheimer lowered shares of ChromaDex from an outperform rating to a market perform rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $5.48.
Get ChromaDex alerts:ChromaDex Stock Down 2.0 %
Shares of NASDAQ:CDXC opened at $1.45 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.04. The firm has a market capitalization of $99.10 million, a P/E ratio of -3.54 and a beta of 1.71. ChromaDex has a 12-month low of $1.44 and a 12-month high of $8.75.
ChromaDex (NASDAQ:CDXC – Get Rating) last issued its earnings results on Wednesday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative net margin of 41.01% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($0.08) EPS. Equities research analysts expect that ChromaDex will post -0.31 earnings per share for the current fiscal year.Insider Activity at ChromaDex
In other ChromaDex news, major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of ChromaDex stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, with a total value of $99,661.42. Following the purchase, the insider now owns 6,925,641 shares in the company, valued at $11,496,564.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 1st quarter worth $29,000. Keebeck Alpha LP bought a new position in ChromaDex in the 4th quarter worth $56,000. Finally, XTX Topco Ltd bought a new position in ChromaDex in the 1st quarter worth $76,000. Institutional investors own 29.64% of the company's stock.
About ChromaDex
(Get Rating)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Macy's Value Lies Beneath its Stores
- The Mattel Train is Ready to Leave the Station
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
ChromaDex (NASDAQ:CDXC – Get Rating) had its price target reduced by HC Wainwright from $7.00 to $5.50 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
據The Fly報道,週一上午發給投資者的一份研究報告中,HC Wainwright將ChromaDex(納斯達克代碼:CDXC-GET評級)的目標價從7.00美元下調至5.50美元。HC Wainwright目前對該股的評級為買入。
A number of other equities research analysts have also issued reports on CDXC. B. Riley lowered shares of ChromaDex from a buy rating to a neutral rating and decreased their target price for the company from $6.00 to $2.40 in a research note on Thursday, August 11th. Oppenheimer lowered shares of ChromaDex from an outperform rating to a market perform rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $5.48.
其他一些股票研究分析師也發佈了關於CDXC的報告。B.萊利在8月11日星期四的一份研究報告中將ChromaDex的股票評級從買入下調至中性,並將該公司的目標價從6.00美元下調至2.40美元。8月16日,週二,奧本海默在一份研究報告中將ChromaDex的股票評級從表現優於大盤下調至市場表現。三名股票研究分析師對該股的評級為持有,兩名分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司的平均評級為持有,平均目標價為5.48美元。
ChromaDex Stock Down 2.0 %
ChromaDex股價下跌2.0%
Shares of NASDAQ:CDXC opened at $1.45 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.04. The firm has a market capitalization of $99.10 million, a P/E ratio of -3.54 and a beta of 1.71. ChromaDex has a 12-month low of $1.44 and a 12-month high of $8.75.
納斯達克:CDXC週一開盤報1.45美元。該公司的50日移動均線切入位在1.76美元,200日移動均線切入位在2.04美元。該公司的市值為9910萬美元,市盈率為-3.54,貝塔係數為1.71。ChromaDex的12個月低點為1.44美元,12個月高位為8.75美元。
Insider Activity at ChromaDex
ChromaDex的內幕活動
In other ChromaDex news, major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of ChromaDex stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, with a total value of $99,661.42. Following the purchase, the insider now owns 6,925,641 shares in the company, valued at $11,496,564.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.
在ChromaDex的其他消息中,大股東Hoi Shuen Solina Holly Chau在6月16日星期四的一筆交易中收購了600,037股ChromaDex股票。該股是以每股1.66美元的平均價格收購的,總價值為99,661.42美元。收購完成後,這位內部人士現在擁有該公司6925,641股,價值11,496,564.06美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個超級鏈接獲得。11.80%的股份由公司內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex in the 4th quarter worth $38,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 1st quarter worth $29,000. Keebeck Alpha LP bought a new position in ChromaDex in the 4th quarter worth $56,000. Finally, XTX Topco Ltd bought a new position in ChromaDex in the 1st quarter worth $76,000. Institutional investors own 29.64% of the company's stock.
機構投資者最近買賣了該公司的股票。Campbell&CO Investment Adviser LLC在第四季度購買了ChromaDex的一個新頭寸,價值3.8萬美元。ProShare Advisors LLC在第四季度購買了ChromaDex的一個新頭寸,價值3.8萬美元。Merriman Wealth Management LLC在第一季度購買了ChromaDex的一個新頭寸,價值2.9萬美元。Keebeck Alpha LP在第四季度購買了ChromaDex的一個新頭寸,價值56,000美元。最後,XTX Topco Ltd在第一季度購買了ChromaDex的一個新頭寸,價值7.6萬美元。機構投資者持有該公司29.64%的股份。
About ChromaDex
關於ChromaDex
(Get Rating)
(獲取評級)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex公司是一家專注於健康老齡化的生物科學公司。該公司通過三個部門運營:消費品;配料;以及分析參考標準和服務。它研究煙酰胺腺嘌呤二核苷酸(NAD+);直接向消費者和經銷商提供含有其專利成分的成品膳食補充劑產品;開發基於專利的成分技術並將其商業化,並將這些成分作為原材料供應給消費品製造商。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Macy's Value Lies Beneath its Stores
- The Mattel Train is Ready to Leave the Station
- 3 WallStreetBets Stocks Wall Street is (Mostly) Bullish On
- Does Micron's Dividend Increase Mean It's Time To Buy?
- What is the NASDAQ Stock Exchange?
- 免費獲取StockNews.com在ChromaDex(CDXC)上的研究報告
- 梅西百貨的價值隱藏在門店下面
- 美泰列車已準備好離開車站
- WallStreetBets股票華爾街(大多)看好
- 美光增加股息是否意味着是時候買入了?
- 什麼是納斯達克證券交易所?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChromaDex Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ChromaDex和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧